(R)-GNE-140

製品コードS6675 バッチS667503

印刷

化学情報

 Chemical Structure Synonyms N/A Storage
(From the date of receipt)
3 years -20°C powder
化学式

C25H23ClN2O3S2

分子量 499.04 CAS No. 2003234-63-5
Solubility (25°C)* 体外 DMSO 100 mg/mL (200.38 mM)
Water Insoluble
Ethanol Insoluble
体内 (毎回新しく調製した物を用意してください)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液(一定の濃度)を調合する

生物活性

製品説明 (R)-GNE-140 is an inhibitory agent for LDHA, LDHB, and LDHC, with IC50 values ​​of 3 nM and 5 nM for LDHA and LDHB, respectively. (R)-GNE-140 is 18 times more potent than its S isomer.
in vitro

(R)-GNE-140 inhibits proliferation in 37 of 347 cancer cell lines tested at a potency cut off of 5 μM. This compound exhibits inhibition with two chondrosarcoma (bone) cancer cell lines that harbored IDH1 mutations (IC50 = 0.8μM). This chemical has submicromolar MiaPaca2 potency and inhibits proliferation in 11% of cancer cell lines in a broad panel. [1]

in vivo

(R)-GNE-140 presents a low Clp, and also had high bioavailability when dosed orally at 5 mg/kg to mice. At higher oral doses, ranging from 50 to 200 mg/kg, this compound displays greater in vivo exposure.[1]

プロトコル(参考用のみ)

細胞アッセイ 細胞株 105KC,JJ012,143B,G84,1321N1,ONS-76,G22,G140,G96,HCC1143,CAL-120,Hs 578T,SISO,SKG-II,HCT-15,KYSE-520,KMRC-1,SNU-475,SNU-423,HT-1080,NCI-H1437,NCI-H1339,LXF-289,MCAS,PA-1,Hs 38.T,59M,MIA PaCa-2,SW 1990,PSN1,GR-M,Hs 746T,MKN-74,S-117,FTC-238,B-CPAP,HEC-265 cell lines
濃度 6 pt dose titration scheme
反応時間 72 h
実験の流れ

Cells are plated using optimal seeding densities in 384-well plates using RPMI, 5% FBS, 100 ug/ml penicillin, 100 units/ml streptomycin. Optimal seeding densities are established for each cell line in order to reach 75-80% confluence at the end of the assay. The following day, cells are treated with (R)-GNE-140 using a 6 pt dose titration scheme. After 72 hours, cell viability is assessed using the CellTiter-Glo® Luminescence Cell Viability assay. Absolute inhibitory concentration (IC) values are calculated using four-parameter logistic curve fitting.

動物実験 動物モデル Female CD-1 mice
投薬量 IV: 1.0 mg/kg; Oral: 5,50,100,200 mg/kg
投与方法 IV / Oral

参考

  • https://www.ncbi.nlm.nih.gov/pubmed/?term=27774125

Selleckの高級品が、幾つかの出版された研究調査結果(以下を含む)で使われた:

Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor models [ J Clin Invest, 2024, 134(17)e177606] PubMed: 39225102
DNAJC12 downregulation induces neuroblastoma progression via increased histone H4K5 lactylation [ J Mol Cell Biol, 2024, mjae056] PubMed: 39716470
Lactate promotes myogenesis via activating H3K9 lactylation-dependent up-regulation of Neu2 expression [ J Cachexia Sarcopenia Muscle, 2023, 10.1002/jcsm.13363] PubMed: 37919243
Host T cell dedifferentiation effects drive HIV-1 latency stability [ J Virol, 2022, jvi0197421] PubMed: 35019721

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。